Researchers and scientists from across the world gathered at the International Coenzyme Q10 Association (ICQA) Conference held in Bologna, Italy to discuss the the latest coenzyme Q10 research.
The findings of the ground-breaking Q-SYMBIO study using Pharma Nord's Bio-Quinone Active Q10 were presented by Australian researcher Dr. Franklin Rosenfeldt. The study looked at the effect of coenzyme Q10 on morbidity and moratality in chronic heart failure patients, reporting a 43 per cent reduction in deaths in the Q10 group.
The life of Professor Svend Aage Mortensen who led the Q-SYMBIO study was commemorated at the conference. His daughter Anne Louise Mortensen, who is a researcher at the Department of Cellular and Molecular Medicine at the University of Copenhagen, received a one-year study grant from the ICQA to continue her father's research into the benefits of coenzyme Q10 for cardiac patients.
Pharma Nord's Q10 was selected for the Q-SYMBIO study due to its high bioavailability. Bent Henriksen O.B.E. (Hon), managing director at Pharma Nord attended the conference and said:
“Coenzyme Q10 has huge potential in the treatment and preventation of cardiovascular disease and it was a step in the right direction to see the Q-SYMBIO study presented on an international stage. We are proud that Pharma Nord's Q10 is the official reference product of international coenzyme Q10 research and look forward to further studies in the coming months and years.”
For more information or to receive a copy of the Q-SYMBIO study, email firstname.lastname@example.org or call Pharma Nord on 01670 534 900.November 2015